OR1D4

Across TCGA pan-cancer cohorts, OR1D4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR1D4 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher OR1D4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR1D4 expression acts as an unfavorable survival marker.

BRCA, KIRC, and LUAD are the cancer types where OR1D4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.027	0.963	<.001	36	view →
KIRC	OS	Median	All	0.181	0.805	.002	21	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	IV	0.075	0.496	.013	6	view →
BLCA	DFS	Median	III,IV	0.100	0.572	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR1D4–BRCA (OS)

Open the BRCA breakdown →